Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma

Annals of Oncology

Volumn 18, Issue 2, 2007, Pages 370-375

  Morschhauser, F ^a   Depil, S ^a   Jourdan, E ^b   Wetterwald, M ^c   Bouabdallah, R ^d   Marit, G ^e   Solal Celigny P ^f   Sebban, C ^g   Coiffier, B ^h   Chouaki, N ⁱ   Bauters, F ^a   Dumontet, Charles ^h,j  

^a Service des Maladies du Sang   (France)

^b Service d'Hematologie   (France)

^c Service d'Hématologie   (France)

^d Service d'Hématologie   (France)

^e Service des Maladies du Sang   (France)

^f Service Oncologie Maladies du Sang   (France)

^g CENTRE LÉON BÉRARD   (France)

^h Institut d'Hématologie   (France)

ⁱ Eli Lilly France   (France)

^j CENTRE HOSPITALIER LYON SUD   (France)

more..

Author keywords

Cisplatin; Dexamethasone; Gemcitabine; Mantle cell lymphoma

Indexed keywords

CISPLATIN; DEXAMETHASONE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMA; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBOLISM; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HEART LEFT VENTRICLE FAILURE; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LIVER TOXICITY; MALE; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS; TUMOR LYSIS SYNDROME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 33847413318     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl395     Document Type: Article

References (28)

1. Samaha H, Dumontet C, Ketterer N et al. Mantle cell lymphoma: A retrospective study of 121 cases. Leukemia 1998; 12: 1281-1287.
2. Zucca E, Roggero E, Pinotti G et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257-262.
3. Teodorovic I, Pittaluga S, Kluin-Nelemans JC et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995; 13: 2819-2826.
4. Bosch F, Lopez-Guillermo A, Campo E et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567-575.
5. Witzig EW. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005; 23: 6409-6414.
6. Romaguera JE, Fayad L, Rodriguez MA et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013-7023.
7. Lazzarino M, Orlandi E, Montillo M et al. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 59-64.
8. Forstpointner R, Dreyling M, Repp R et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064-3071.
9. Seymour JF, Grigg AP, Szer J, Fox RM. Cisplatin, fludarabine, and cytarabine: A novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma. Cancer 2002; 94: 585-593.
10. Johnson SA. Nucleoside analogues in the treatment of haematological malignancies. Expert Opin Pharmacother 2001; 2: 929-943.
11. Peters GJ, Ruiz van Haperen VW, Bergman AM et al. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 1996; 23: 16-24.
12. Baetz T, Belch A, Couban S et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003; 14: 1762-1767.
13. Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol 2000; 18: 2615-2619.
14. Zinzani PL, Magagnoli M, Bendandi M et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 1998; 9: 1351-1353.
15. Fossa A, Santoro A, Hiddemann W et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3786-3792.
16. Larson BJ, Waples JM, Pusateri A et al. A phase II study of gemcitabine in patients with relapsed or refractory low-grade non-Hodgkin lymphoma. Am J Clin Oncol 2005; 28: 165-168.
17. Dumontet C, Morschhauser F, Solal-Celigny P et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 2001; 113: 772-778.
18. Savage DG, Rule SA, Tighe M et al. Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 2000; 11: 595-597.
19. Bouabdallah R, Delmer A, Xerri L et al. ESHAP chemotherapy regimen and 13-CIS-retinoic acid in elderly patients with untreated poor-prognosis peripheral T cell lymphoma: A GELA phase II trial of feasibility and efficacy. Ann Oncol 2005; 16: V131.
20. Cheson BD, Homing SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
21. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
22. Crump M, Baetz T, Couban S et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004; 101: 1835-1842.
23. Emmanouilides C, Colovos G, Pinter-Brown L et al. Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma 2004; 5: 45-49.
24. Ng M, Waters J, Cunningham D et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 2005; 92: 1352-1357.
25. Wenger C, Stem M, Herrmann R et al. Rituximab plus gemcitabine: A therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma? Leuk Lymphoma 2005; 46: 71-75.
26. Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288-1294.
27. O'Connor OA, Wright J, Moskowitz C et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676-684.
28. Zheng B, Georgakis GV, Li Y et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004; 10: 3207-3215.